What is INVA's current stock price?

INVA (Innoviva, Inc.) is currently trading at $22.46 with a market cap of $1.66B.

What sector is Innoviva, Inc. in?

Innoviva, Inc. (INVA) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is INVA a good stock to buy?

Analysts have a Buy consensus on INVA with a price target of $40.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

INVA Innoviva, Inc.

Healthcare

$22.46+1.17%ClosedMarket Cap: $1.66B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

5.64

PEG

0.01

P/B

1.24

P/S

3.91

EV/EBITDA

3.09

DCF Value

$62.92

FCF Yield

10.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

76.2%

Operating Margin

14.8%

Net Margin

118.9%

ROE

47.6%

ROA

27.5%

ROIC

2.9%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$98.0M	$186.6M	$—
Q4 null	$118.0M	$164.2M	$—
FY null	$425.1M	$271.2M	$—
Q3 null	$107.8M	$89.9M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$40.00

Target (Median)

$42.00

Target Range

$32.00 - $46.00

0 Strong Buy4 Buy0 Hold1 Sell0 Strong Sell

BTIGBuy

2026-05-07

BTIGBuy

2026-02-26

HC Wainwright & Co.Buy

2025-12-16

Cantor FitzgeraldOverweight

2025-11-06

HC Wainwright & Co.Buy

2025-08-11

Trading Activity

Insider Trades

View All

Zhen Marianneofficer: Chief Accounting Officer

SellFri May 22

Raifeld Paveldirector, officer: Chief Executive Officer

SellFri May 22

Raifeld Paveldirector, officer: Chief Executive Officer

SellFri May 22

Basso Stephenofficer: Chief Financial Officer

SellFri May 22

Basso Stephenofficer: Chief Financial Officer

SellFri May 22

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.38

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Peers